Data in hand, Cytokinetics looks to expanded Myqorzo approval
Data in hand, Cytokinetics looks to expanded Myqorzo approval
Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering and developing muscle biology-directed therapies for diseases of impaired muscle function, including cardiac myosin modulators for heart failure and skeletal muscle activators for ALS and SMA.
Company Info
Sector:Cardiovascular / Muscle biology
Headquarters:South San Francisco, California, USA
Founded:1998
Website:cytokinetics.com/
Recent News
ESC: Cytokinetics data is first to demonstrate benefit for nHCM
ESC: Cytokinetics data is first to demonstrate benefit for nHCM
Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
Endpoints News reports Cytokinetics filed a patent infringement lawsuit against Bristol Myers Squibb, escalating competition in the cardiac myosin modulator space.